The effect of mitomycin C on superficial bladder cancer

M. S. Soloway, W. M. Murphy, M. D. DeFuria, S. Crooke, P. Finebaum

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


A course of intravesical mitomycin C, consisting of 8 weekly doses of 30 or 40 mg., was evaluated in 16 patients with superficial bladder cancer (stages O and A). Cystoscopically documented tumor was destroyed completely in 11 patients (69 per cent), while 3 patients exhibited partial tumor regression. Two patients had only multifocal, grade 3 carcinoma in situ and both had a complete response with negative biopsies and cytology at the 12-week evaluation. Toxicity was minimal. Further data, including longer followup, are needed to define the potentially promising role of this agent in the over-all management of superficial bladder cancer.

Original languageEnglish (US)
Pages (from-to)646-648
Number of pages3
JournalUnknown Journal
Issue number5
StatePublished - 1981
Externally publishedYes

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'The effect of mitomycin C on superficial bladder cancer'. Together they form a unique fingerprint.

Cite this